Video Summary
Moderna shares more than doubled after the US drugmaker reported positive late-stage results for a personalized mRNA skin cancer vaccine developed with Merck. The treatment reduced cancer recurrence and the spread of tumors when combined with Merck’s Keytruda, compared with Keytruda alone.. Subscribe to us on YouTube: http://ow.ly/Zvqj30aIsgY. Facebook: https://www.facebook.com/cgtnafrica/.
Video Details
Source: Global Business
Publication Date: 2026-08-20T12:08:33Z
Original Link: Watch the video on YouTube
Full Description
Moderna shares more than doubled after the US drugmaker reported positive late-stage results for a personalized mRNA skin cancer vaccine developed with Merck. The treatment reduced cancer recurrence and the spread of tumors when combined with Merck’s Keytruda, compared with Keytruda alone.
Subscribe to us on YouTube: http://ow.ly/Zvqj30aIsgY
Follow us on:
Facebook: https://www.facebook.com/cgtnafrica/
Twitter: https://twitter.com/cgtnafrica
Instagram: https://www.instagram.com/cgtn_africa/
French 
English 
Spanish 
Portuguese 
Russian 
Chinese 
Dutch 
Italian 
Danish 
Greek 
Finnish 
Hindi 
Japanese 
Korean